Wie hoch ist der Preis für AlloVir, Inc. (ALVR)

Preis für AlloVir, Inc. (ALVR) ist $9.81

Wie hoch ist die Marktkapitalisierung für AlloVir, Inc. (ALVR)

Marktkapitalisierung für AlloVir, Inc. (ALVR) ist $48.68M

AlloVir, Inc. (ALVR) Ausstehende Aktien

AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.

Jahr	Ausstehende Aktien	ändert
2026 (TTM)	23.80M	379.57%
2024	4.96M	10.90%
2023	4.47M	35.75%
2022	3.30M	22.10%
2021	2.70M	133.42%
2020	1.16M	-36.07%
2019	1.81M	38.40%
2018	1.31M	0.00%

Jahr

Ausstehende Aktien

ändert

2026 (TTM)

23.80M

379.57%

2024

4.96M

10.90%

2023

4.47M

35.75%

2022

3.30M

22.10%

2021

2.70M

133.42%

2020

1.16M

-36.07%

2019

1.81M

38.40%

2018

1.31M

0.00%

Unternehmen	Ausstehende Aktien	Unterschied	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	966.93%	US
Argenx SE ARGX.US	62.19M	161.31%	NL
CSL Limited CSL.AX	483.58M	1,932.06%	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	396.00M	1,564.05%	US

Unternehmen

Ausstehende Aktien

Unterschied

Land